Abstract
Purpose
Materials and Methods
Results
Figures and Tables
Fig. 1
Selection of study population. KorHF, The Korean Heart Failure registry; SUGAR, Survey of Guideline Adherence for Treatment of Systolic Heart Failure in Real World; LVEF, left ventricular ejection fraction; BMI, body mass index.
![ymj-59-57-g001](/upload/SynapseData/ArticleImage/0069ymj/ymj-59-57-g001.jpg)
Fig. 2
Kaplan-Meier curve for incidence of the primary endpoint in the male population. BMI, body mass index.
![ymj-59-57-g002](/upload/SynapseData/ArticleImage/0069ymj/ymj-59-57-g002.jpg)
Fig. 3
Kaplan-Meier curve for incidence of the primary endpoint in the female population. BMI, body mass index.
![ymj-59-57-g003](/upload/SynapseData/ArticleImage/0069ymj/ymj-59-57-g003.jpg)
Table 1
Baseline Characteristics of the Male Population According to BMI
![ymj-59-57-i001](/upload/SynapseData/ArticleImage/0069ymj/ymj-59-57-i001.jpg)
BMI, body mass index; SBP, systolic blood pressure; BPM, beats per minute; HF, heart failure; LVEDD, left ventricular end diastolic dimension; LVESD, left ventricular end systolic dimension; LBBB, left bundle branch block; NYHA, New York Heart Association; HTN, hypertension; DM, diabetes mellitus; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; BUN, blood urea nitrogen; Cr, creatinine; BNP, brain natriuretic peptides; NT-proBNP, N terminal pro brain natriuretic peptides; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist.
Values are expressed as mean±SD or n (%).
Table 2
Baseline Characteristics of the Female Population According to BMI
![ymj-59-57-i002](/upload/SynapseData/ArticleImage/0069ymj/ymj-59-57-i002.jpg)
BMI, body mass index; SBP, systolic blood pressure; BPM, beats per minute; HF, heart failure; LBBB, left bundle branch block; NYHA, New York Heart Association; HTN, hypertension; DM, diabetes mellitus; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; BUN, blood urea nitrogen; Cr, creatinine; BNP, brain natriuretic peptides; NT-proBNP, N terminal pro brain natriuretic peptides; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist.
Values are expressed as mean±SD or n (%).
Table 3
Incidence of the Primary Endpoint According to BMI Category
![ymj-59-57-i003](/upload/SynapseData/ArticleImage/0069ymj/ymj-59-57-i003.jpg)
Table 4
Adjusted Hazard Ratios for the Primary Endpoint According to BMI Category
![ymj-59-57-i004](/upload/SynapseData/ArticleImage/0069ymj/ymj-59-57-i004.jpg)
BMI, body mass index; CI, confidence interval.
Data were presented as hazard ratio (95% CI). Adjusted for age, hypertension, diabetes, chronic kidney disease, ischemic etiology, New York Heart Association class, previous myocardial infarction, left ventricle ejection fraction, N terminal pro brain natriuretic peptides, left ventricle end diastole dimension, hemoglobin, discharge medication (angiotensin converting enzyme inhibitor or angiotensin receptor blocker and Beta blocker).
*p value<0.05.
References
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)